This comprehensive bibliometric analysis of 1,428 publications from the WoSCC reveals the rapid expansion and maturation of research on hypofractionated radiotherapy (HFRT) for prostate cancer, characterized by an average annual growth rate of 13.28% since 2020. Led by prominent contributions from the United States, Italy, and the University of Toronto, the field has evolved from foundational radiobiological concepts and early conformal techniques toward current research hotspots focused on high-precision delivery, such as image-guided radiotherapy (IGRT) and stereotactic body radiation therapy (SBRT), as well as robust clinical validation through randomized non-inferiority trials. The findings highlight a multidisciplinary ecosystem that increasingly integrates technological advancements with quality-of-life assessments. Moving forward, the research trajectory is expected to prioritize personalized adaptive radiotherapy, biomarker integration, and the resolution of practical implementation challenges to further refine and enhance clinical outcomes for prostate cancer patients.
Meng et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: